JP2003502283A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003502283A5 JP2003502283A5 JP2000612337A JP2000612337A JP2003502283A5 JP 2003502283 A5 JP2003502283 A5 JP 2003502283A5 JP 2000612337 A JP2000612337 A JP 2000612337A JP 2000612337 A JP2000612337 A JP 2000612337A JP 2003502283 A5 JP2003502283 A5 JP 2003502283A5
- Authority
- JP
- Japan
- Prior art keywords
- dendritic cells
- type lectin
- cells
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000342 C-Type Lectins Proteins 0.000 description 31
- 102000003930 C-Type Lectins Human genes 0.000 description 31
- 210000004443 dendritic cell Anatomy 0.000 description 28
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 239000012634 fragment Substances 0.000 description 12
- 239000002523 lectin Substances 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- -1 mannose carbohydrate Chemical class 0.000 description 6
- 230000028993 immune response Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 229920000057 Mannan Polymers 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- 108010089814 Plant Lectins Proteins 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 description 3
- 239000003726 plant lectin Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- WPICPWIIIBCXCV-UHFFFAOYSA-N Pradimicin A Natural products CNC1C(C)OC(OC2C3=CC(C)=C(C(=O)NC(C)C(O)=O)C(O)=C3C3=C(O)C=4C(=O)C5=CC(OC)=CC(O)=C5C(=O)C=4C=C3C2O)C(O)C1OC1OCC(O)C(O)C1O WPICPWIIIBCXCV-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229930191090 pradimicin Natural products 0.000 description 1
- WPICPWIIIBCXCV-NJGWPHBESA-N pradimicin A Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@H]2C3=CC(C)=C(C(=O)N[C@H](C)C(O)=O)C(O)=C3C3=C(O)C=4C(=O)C5=CC(OC)=CC(O)=C5C(=O)C=4C=C3[C@@H]2O)O[C@H](C)[C@@H]1NC)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O WPICPWIIIBCXCV-NJGWPHBESA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99201204.7 | 1999-04-19 | ||
| EP19990201204 EP1046651A1 (en) | 1999-04-19 | 1999-04-19 | Composition and method for modulating dendritic cell-T interaction |
| US17692400P | 2000-01-20 | 2000-01-20 | |
| US60/176,924 | 2000-01-20 | ||
| PCT/NL2000/000253 WO2000063251A1 (en) | 1999-04-19 | 2000-04-19 | Composition and method for modulating dendritic cell-t cell interaction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010176824A Division JP5363432B2 (ja) | 1999-04-19 | 2010-08-05 | 樹状細胞−ｔ細胞の相互作用を調節するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003502283A JP2003502283A (ja) | 2003-01-21 |
| JP2003502283A5 true JP2003502283A5 (enExample) | 2008-01-10 |
| JP4989820B2 JP4989820B2 (ja) | 2012-08-01 |
Family
ID=8240111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000612337A Expired - Fee Related JP4989820B2 (ja) | 1999-04-19 | 2000-04-19 | 樹状細胞−ｔ細胞の相互作用を調節するための組成物及び方法 |
| JP2010176824A Expired - Fee Related JP5363432B2 (ja) | 1999-04-19 | 2010-08-05 | 樹状細胞−ｔ細胞の相互作用を調節するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010176824A Expired - Fee Related JP5363432B2 (ja) | 1999-04-19 | 2010-08-05 | 樹状細胞−ｔ細胞の相互作用を調節するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7148329B1 (enExample) |
| EP (3) | EP1046651A1 (enExample) |
| JP (2) | JP4989820B2 (enExample) |
| KR (3) | KR100952883B1 (enExample) |
| AT (2) | ATE472558T1 (enExample) |
| AU (1) | AU776317B2 (enExample) |
| CA (1) | CA2330231C (enExample) |
| DE (2) | DE60039151D1 (enExample) |
| DK (2) | DK1516881T3 (enExample) |
| ES (2) | ES2307502T3 (enExample) |
| NZ (1) | NZ508723A (enExample) |
| PT (2) | PT1516881E (enExample) |
| WO (1) | WO2000063251A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1046651A1 (en) * | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| US6515124B2 (en) * | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
| US7560534B2 (en) * | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| KR100643818B1 (ko) * | 2000-05-08 | 2006-11-10 | 셀덱스 쎄라퓨틱스, 인크. | 수상세포에 대한 인간 모노클로날 항체 |
| EP1339830A2 (en) * | 2000-12-21 | 2003-09-03 | Stichting Katholieke Universiteit | Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| US20030013081A1 (en) | 2001-06-26 | 2003-01-16 | Olson William C. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| US7022323B2 (en) | 2001-06-26 | 2006-04-04 | Progenics Pharmaceuticals, Inc. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| ES2197826B1 (es) * | 2002-06-21 | 2005-04-01 | Consejo Superior De Investigaciones Cientificas | Compuesto terapeutico frente a la infeccion por leishmania y su uso. |
| US7541032B2 (en) * | 2002-09-20 | 2009-06-02 | Stichting Katholieke Universiteit | Antigen uptake receptor for Candida albicans on dendritic cells |
| US7691591B2 (en) * | 2002-09-20 | 2010-04-06 | Stichting Katholieke Universiteit | Methods of identifying and isolating cells expressing DC-sign |
| US20040146948A1 (en) * | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| US7427469B2 (en) | 2002-11-05 | 2008-09-23 | Institut Pasteur | Method of treating cytomegalovirus with DC-SIGN blockers |
| BR0315975A (pt) * | 2002-11-05 | 2005-09-20 | Pasteur Institut | Usos de uma quantidade de um modulador e de um bloqueador de dc-sign, composição farmacêutica, métodos para identificar um modulador e um bloqueador de dc-sign, bloqueador de dc-sign isolado, e, método para alvejar uma molécula objeto a uma célula que expressa um receptore de dc-sign |
| EP1417965A1 (en) * | 2002-11-07 | 2004-05-12 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | C-type lectin binding molecules, identification and uses thereof |
| EP1594533B1 (en) | 2003-01-31 | 2012-04-11 | Celldex Research Corporation | Antibody vaccine conjugates and uses therefor |
| US9259459B2 (en) | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| AU2011211337B2 (en) * | 2003-10-16 | 2014-10-02 | Cancure Limited | Immunomodulating compositions and uses therefor |
| EP2591786B1 (en) * | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| EP1699487A4 (en) * | 2003-12-15 | 2009-07-08 | Alexion Pharma Inc | NEW ANTI-DC-SIGN ANTIBODIES |
| EP1761248B1 (en) | 2004-03-19 | 2012-05-23 | Rodos BioTarget GmbH | Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds |
| DK1765294T3 (da) * | 2004-05-12 | 2008-11-10 | Baxter Int | Nukleinsyremikrokugler samt deres fremstilling og afgivelse |
| EP1758558B1 (en) * | 2004-05-12 | 2013-10-16 | Baxter International Inc. | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
| AU2006252406B2 (en) | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| FR2895262B1 (fr) * | 2005-12-22 | 2009-07-17 | Lab Francais Du Fractionnement | Inhibition de la reponse immunitaire anti-fviii |
| AT503387B1 (de) * | 2006-03-27 | 2008-05-15 | Univ Wien | Pharmazeutische zusammensetzung zur vorbeugung von infektionen |
| SG173337A1 (en) | 2006-07-21 | 2011-08-29 | California Inst Of Techn | Targeted gene delivery for dendritic cell vaccination |
| BRPI0807160A2 (pt) | 2007-02-02 | 2018-09-25 | Baylor Res Institute | vacinas baseadas no direcionamento de antígeno ao dcir expresso em células apresentadoras de antígeno |
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| ES2536900T3 (es) * | 2007-02-02 | 2015-05-29 | Baylor Research Institute | Antígenos multivariables en complejo con anticuerpo monoclonal humanizado de dirección |
| BRPI0815848A2 (pt) | 2007-08-30 | 2017-06-06 | The Burnet Inst | composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit. |
| EP2207798A2 (en) | 2007-10-29 | 2010-07-21 | Virginia Tech Intellectual Properties, Inc. | Porcine dc-sign, icam-3 and lsectin and uses thereof |
| BRPI0820270A2 (pt) | 2007-11-07 | 2015-06-16 | Celldex Therapeutics Inc | Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular. |
| WO2011011584A1 (en) | 2009-07-24 | 2011-01-27 | Immune Design Corp | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
| WO2011055550A1 (ja) * | 2009-11-05 | 2011-05-12 | 国立大学法人大阪大学 | 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法 |
| JP5690132B2 (ja) | 2010-06-17 | 2015-03-25 | 株式会社マーレ フィルターシステムズ | エンジンの換気システム |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| AU2011289579B2 (en) | 2010-08-10 | 2016-11-17 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| EP2831095B1 (en) | 2012-03-30 | 2018-11-28 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign |
| US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| EP3549605A1 (en) * | 2012-04-04 | 2019-10-09 | Vaxform LLC | Adjuvant system for oral vaccine administration |
| EP2897641B1 (en) * | 2012-09-18 | 2018-07-18 | University of Washington through its Center for Commercialization | Compositions and methods for antigen targeting to cd180 |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| LT3107563T (lt) | 2014-02-21 | 2021-07-12 | Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto | Gliko-nukreipiantys terapiniai agenai |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| CN106659774A (zh) | 2014-05-16 | 2017-05-10 | 贝勒研究院 | 用于治疗自身免疫和炎性病症的方法和组合物 |
| US10688178B2 (en) | 2015-06-30 | 2020-06-23 | Osaka University | AntiPlexin A1 agonist antibody |
| CN108210503A (zh) * | 2016-12-10 | 2018-06-29 | 高尚先 | 甘露糖在用于提高Treg细胞数量及其Foxp3因子表达水平的新用途 |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| EA202092723A1 (ru) | 2018-05-09 | 2021-04-09 | Зе Юниверсити Оф Чикаго | Композиции и способы, касающиеся иммунной толерантности |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US891992A (en) | 1907-06-27 | 1908-06-30 | Henry Hess | Method of forming conically-shaped ends upon rollers and other objects. |
| US5332567A (en) * | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
| US6248332B1 (en) * | 1990-10-05 | 2001-06-19 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| IE922308A1 (en) * | 1991-07-16 | 1993-01-27 | Bristol Myers Squibb Co | Inhibition of non-cd4 mediated hiv infection |
| WO1995003234A1 (en) | 1993-07-22 | 1995-02-02 | Precision Valve Corporation | Multi-directional actuation overcap |
| US6084067A (en) | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
| AUPM322393A0 (en) * | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| AU2670995A (en) | 1994-05-26 | 1995-12-21 | Innogenetics N.V. | New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness |
| US5548275A (en) * | 1995-01-23 | 1996-08-20 | Shambayati; Ali | Alarm system for enclosing and protecting an area |
| US5643786A (en) | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
| WO1996023882A1 (en) * | 1995-01-31 | 1996-08-08 | The Rockefeller University | IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF |
| US5871964A (en) * | 1996-07-15 | 1999-02-16 | Incyte Pharmaceuticals, Inc. | Human C-type lectin |
| US6046158A (en) * | 1996-12-20 | 2000-04-04 | Board Of Regents The University Of Texas Systems | Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof |
| US5935813A (en) * | 1997-03-20 | 1999-08-10 | Incyte Pharmaceuticals, Inc. | Human pancreatitis-associated protein |
| WO1998049306A1 (en) * | 1997-04-29 | 1998-11-05 | Incyte Pharmaceuticals, Inc. | Human c-type lectin |
| EP0984984A2 (en) * | 1997-06-03 | 2000-03-15 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS |
| US6273443B1 (en) * | 1998-06-01 | 2001-08-14 | Sunrise Medical Hhg Inc. | Universal elevating leg rest assembly |
| EP1046651A1 (en) * | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| IL147902A0 (en) * | 1999-08-12 | 2002-08-14 | Agensys Inc | C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| EP1339830A2 (en) | 2000-12-21 | 2003-09-03 | Stichting Katholieke Universiteit | Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| US20030232745A1 (en) | 2001-06-26 | 2003-12-18 | Olson William C. | Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection |
| US7022323B2 (en) * | 2001-06-26 | 2006-04-04 | Progenics Pharmaceuticals, Inc. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| EP1542354B1 (en) * | 2003-12-09 | 2021-02-03 | Synergy Microwave Corporation | Integrated ultra low noise microwave wideband push-push vco |
-
1999
- 1999-04-19 EP EP19990201204 patent/EP1046651A1/en not_active Withdrawn
-
2000
- 2000-04-19 US US09/719,961 patent/US7148329B1/en not_active Expired - Fee Related
- 2000-04-19 KR KR1020087023697A patent/KR100952883B1/ko not_active Expired - Fee Related
- 2000-04-19 AT AT04078220T patent/ATE472558T1/de active
- 2000-04-19 EP EP00921181A patent/EP1086137B1/en not_active Expired - Lifetime
- 2000-04-19 DK DK04078220.3T patent/DK1516881T3/da active
- 2000-04-19 EP EP04078220A patent/EP1516881B1/en not_active Expired - Lifetime
- 2000-04-19 KR KR1020007014459A patent/KR20010071530A/ko not_active Ceased
- 2000-04-19 WO PCT/NL2000/000253 patent/WO2000063251A1/en not_active Ceased
- 2000-04-19 PT PT04078220T patent/PT1516881E/pt unknown
- 2000-04-19 PT PT00921181T patent/PT1086137E/pt unknown
- 2000-04-19 AU AU41526/00A patent/AU776317B2/en not_active Ceased
- 2000-04-19 CA CA2330231A patent/CA2330231C/en not_active Expired - Fee Related
- 2000-04-19 AT AT00921181T patent/ATE398140T1/de active
- 2000-04-19 NZ NZ508723A patent/NZ508723A/en not_active IP Right Cessation
- 2000-04-19 DE DE60039151T patent/DE60039151D1/de not_active Expired - Lifetime
- 2000-04-19 ES ES00921181T patent/ES2307502T3/es not_active Expired - Lifetime
- 2000-04-19 DK DK00921181T patent/DK1086137T3/da active
- 2000-04-19 DE DE60044621T patent/DE60044621D1/de not_active Expired - Lifetime
- 2000-04-19 ES ES04078220T patent/ES2346877T3/es not_active Expired - Lifetime
- 2000-04-19 KR KR1020077020353A patent/KR100923340B1/ko not_active Expired - Fee Related
- 2000-04-19 JP JP2000612337A patent/JP4989820B2/ja not_active Expired - Fee Related
-
2003
- 2003-07-23 US US10/625,202 patent/US8105599B2/en not_active Expired - Fee Related
- 2003-07-23 US US10/625,204 patent/US7285642B2/en not_active Expired - Fee Related
-
2007
- 2007-10-22 US US11/977,151 patent/US8058400B2/en not_active Expired - Fee Related
-
2010
- 2010-08-05 JP JP2010176824A patent/JP5363432B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003502283A5 (enExample) | ||
| EP3048115B1 (en) | Monoclonal antibodies for ebola and marburg viruses | |
| JP3343912B2 (ja) | パピローマウイルス様キメラ粒子 | |
| CA2347411A1 (en) | Virus-like particles for the induction of autoantibodies | |
| JP5097400B2 (ja) | 複合ワクチン | |
| RU2721574C2 (ru) | Вакцинная композиция против злокачественной опухоли | |
| JP2023075196A (ja) | 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体 | |
| JP2002504334A (ja) | Ｏｘ−４０レセプター結合因子又はそれをコードする核酸を含む組成物並びに抗原特異的免疫応答を増強するための方法 | |
| JP2001517069A (ja) | 結核の免疫治療および診断のための化合物および方法 | |
| CN108697785A (zh) | Zika病毒疫苗 | |
| ES2373055T3 (es) | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. | |
| JP2007501602A5 (enExample) | ||
| CZ20003652A3 (en) | Purified polypeptide, prevention method of tuberculosis, pharmaceutical mixture | |
| JPS63183600A (ja) | ヒト乳頭腫ウイルスの診断用ペプチド | |
| JP2004515202A5 (enExample) | ||
| JP2009108092A (ja) | 肝臓およびリンパ節中の類洞内皮細胞上において、新規なｉｃａｍ−３結合レセプターの結合活性を調節するための方法 | |
| CN105378479A (zh) | 用于预测免疫疗法的临床效果的方法 | |
| JPH10501417A (ja) | 組換えアレルゲン、そのフラグメント、対応する組換えｄｎａ分子、該ｄｎａ分子を含むベクターおよび宿主、ならびに、該アレルゲンおよびフラグメントの診断および治療用途 | |
| JP2010535504A5 (enExample) | ||
| KR20070067719A (ko) | 백신용 면역조절제 | |
| SA110310855B1 (ar) | استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي | |
| JP7045024B2 (ja) | マラリアワクチン | |
| CA3218851A1 (en) | Amino acids, nucleotides and vectors expressing the same and uses thereof in preventing sarbecovirus infection | |
| JPH08512045A (ja) | ヒトパピローマウイルスの合成ペプチド | |
| CN113876939A (zh) | 登革次单位疫苗组成物 |